Covidien Awarded $176.5 Million Verdict in Patent Litigation against Ethicon Endo-Surgery

  Covidien Awarded $176.5 Million Verdict in Patent Litigation against Ethicon
  Endo-Surgery

Business Wire

NEW HAVEN, Conn. -- March 29, 2013

Covidien (NYSE: COV), a leading global provider of healthcare products, today
announced that it has won a patent infringement suit against Ethicon
Endo-Surgery, Inc., a Johnson & Johnson company, relating to Ethicon's
Harmonic® line of ultrasonic surgical products.

The federal court awarded Covidien a $176.5 million verdict upon ruling that
several claims of Covidien’s patents were valid, enforceable, and infringed by
Ethicon. The amount of the verdict, which could be appealed, was based on an 8
percent royalty rate on infringing sales through March 2012, plus prejudgment
interest.

“As a global healthcare market leader, Covidien invests significant resources
into creating and developing medical innovations. We are pleased that the
federal court recognized our innovation in ultrasonic surgical devices,
finding our patents both valid and infringed by Ethicon Endo-Surgery. We will
continue to vigorously protect our innovative products, solutions and
intellectual property,” stated Chris Barry, President, Advanced Surgical
Technologies, Covidien.

The federal court found that Ethicon infringed Covidien’s U.S. Patents
6,063,050, 6,468,286, and 6,682,544, each relating to ultrasonic cutting and
coagulation surgical devices.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers value
through clinical leadership and excellence. Covidien manufactures, distributes
and services a diverse range of industry-leading product lines in three
segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012
revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70
countries, and its products are sold in over 140 countries. Please visit
www.covidien.com to learn more about our business.

Contact:

Covidien
Marguerite Copel, 203-821-4720
Vice President
Communications
marguerite.copel@covidien.com
or
John Jordan, 508-452-4891
Manager
Communications
john.jordan@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com
 
Press spacebar to pause and continue. Press esc to stop.